113
Participants
Start Date
March 31, 2022
Primary Completion Date
January 17, 2023
Study Completion Date
January 17, 2023
HTD1801
HTD1801 administered orally BID as two capsules
Placebo
Matching placebo administered orally BID as two to four capsules
HTD1801
HTD1801 administered orally BID as four capsules
Peking University People's Hospital, Beijing
The Second Hospital of Jilin University, Changchun
The First People's Hospital of Changde City, Changde
The Fourth Affiliated Hospital of Harbin Medical University, Harbin
Huizhou Municipal Central Hospital, Huizhou
Jinan Central Hospital, Jinan
Liaocheng People's Hospital, Liaocheng
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang
Nanjing First Hospital, Nanjing
Nanjing Jiangning Hospital, Nanjing
Sir Run Run Hospital Nanjing Medical University, Nanjing
The First Affiliated Hospital of Nanyang Medical College, Nanyang
Yan'an University Affiliated Hospital, Yanan
Affiliated Hospital of Jiangsu University, Zhenjiang
Shenzhen HighTide Biopharmaceutical Ltd.
UNKNOWN
HighTide Biopharma Pty Ltd
INDUSTRY